drugset / Trial / NCT00541281
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
Phase 2
Completed
150 enrolled
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sanofi · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
we propose to randomize patients with hormone resistant prostate cancer between docetaxel/estramustine/prednisone and docetaxel/prednisone in a phase II study. The principal endpoint will be the efficacy in term of PSA response.
Timeline
- Start
- 2003-12
- Primary completion
- —
- Completion
- 2006-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | estramustine | Other / unclassified | 420 mg | — |
| Comparator | Docetaxel | Small molecule | 35 mg/m2 | — |
| Comparator | Prednisone | Other / unclassified | 10 mg | — |